# the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer

> **NCT05131243** · NA · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Cancer Stage II
- Colorectal Cancer Stage III

## Interventions

- **PROCEDURE:** Chemotherapy time
- **PROCEDURE:** Chemotherapy time

## Key facts

- **NCT ID:** NCT05131243
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131243, "the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05131243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*